FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its cross-appeal) of the North Carolina District Court's August 2025 ruling. The dismissal will leave in place the ruling in NeoGenomics' favor. That ruling, issued by the District Court for the Middle District of North Carolina, granted NeoGenomics' motion for summar ...

NeoGenomics (NasdaqCM:NEO) FY Conference December 02, 2025 02:30 PM ET Company ParticipantsWarren Stone - President and COOTony Zook - CEOConference Call ParticipantsDave Westenberg - Life Sciences Tools & Diagnostics AnalystDave WestenbergAll right. So, I'm Dave Westenberg, the Life Science Tools and Diagnostics Analyst here at Piper. Up next here we have NeoGenomics. Very happy to present NeoGenomics CEO Tony Zook and COO Warren Stone. Thank you very much for both coming. So your clinical business is perf ...

Core Insights - NeoGenomics will present research at ISLB 2025 demonstrating high concordance between its RaDaR ST and RaDaR 1.0 MRD assays [1] Group 1 - The presentation will include four additional posters alongside the main research findings [1]

Financial Performance - Clinical revenue increased by 18%[17], or 15% excluding Pathline[20] - Clinical volume grew by 15%[19], or 10% excluding Pathline[20] - NGS revenue increased by 24% year-over-year[20] - Adjusted gross profit was $85 million, a 7% increase from the prior year[19, 20] - Adjusted EBITDA was $12 million, representing a 9% decrease[19] Financial Overview (Q3 2025 vs Q3 2024) - Revenue increased by 11.9% to $187.8 million[22] from $167.8 million[22] - Adjusted gross profit increased by 6.6% to $85.4 million[22] from $80.1 million[22] - Adjusted gross margin decreased by 228 bps to 45.5%[22] from 47.8%[22] - Adjusted EBITDA decreased by 8.5% to $12.2 million[22] from $13.4 million[22] - Cash and cash equivalents decreased by 54.7% to $164.1 million[22] from $361.9 million[22] FY 2025 Guidance - Revenue is projected to be between $720 million and $726 million, representing a year-over-year growth of 9% to 10%[21] - Adjusted EBITDA is projected to be between $41 million and $44 million, representing a year-over-year growth of 3% to 10%[21]